ICUI
ICU Medical, Inc. NASDAQ Listed Mar 31, 1992$123.07
Mkt Cap $3.1B
52w Low $107.00
30.2% of range
52w High $160.29
50d MA $128.75
200d MA $133.60
P/E (TTM)
4001.7x
EV/EBITDA
14.1x
P/B
1.4x
Debt/Equity
0.7x
ROE
0.0%
P/FCF
38.3x
RSI (14)
—
ATR (14)
—
Beta
0.85
50d MA
$128.75
200d MA
$133.60
Avg Volume
291.2K
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
951 Calle Amanecer · San Clemente, CA 92673 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | 1.78 | 1.97 | +10.7% | 123.07 | +0.0% | +2.7% | — | — | — | — | — |
| Feb 19, 2026 | AMC | 1.68 | 1.91 | +13.7% | 149.74 | +0.3% | +4.9% | +1.2% | +1.8% | +3.6% | +0.7% | — |
| Nov 6, 2025 | AMC | 1.43 | 2.03 | +42.0% | 129.67 | +12.3% | +8.1% | +7.4% | +10.4% | +7.3% | +6.8% | — |
| Aug 7, 2025 | AMC | 1.44 | 2.10 | +45.8% | 129.91 | -4.0% | -13.1% | -16.8% | -15.1% | -12.1% | -13.9% | — |
| May 8, 2025 | AMC | 1.23 | 1.72 | +39.8% | 142.87 | -5.3% | -3.2% | +1.0% | +0.5% | -4.9% | -1.6% | — |
| Feb 27, 2025 | AMC | 1.48 | 2.11 | +42.6% | 149.75 | -4.8% | -2.3% | -5.5% | -5.9% | -4.1% | -5.0% | — |
| Nov 12, 2024 | AMC | 1.25 | 1.59 | +27.2% | 178.01 | +8.6% | -1.8% | -3.4% | -5.7% | -4.5% | -4.7% | — |
| Aug 7, 2024 | AMC | 0.98 | 1.56 | +59.2% | 121.79 | +17.8% | +24.3% | +25.4% | +21.6% | +23.2% | +21.5% | — |
| May 7, 2024 | AMC | 0.84 | 0.96 | +14.3% | 101.77 | -3.4% | -1.1% | +4.5% | +5.2% | +6.5% | +3.4% | — |
| Feb 27, 2024 | AMC | 1.18 | 1.57 | +33.1% | 106.81 | +5.0% | +5.3% | +2.3% | -1.3% | +0.1% | -4.0% | — |
| Nov 6, 2023 | AMC | 1.29 | 1.57 | +21.7% | 102.00 | -0.6% | -17.3% | -15.0% | -20.5% | -19.7% | -19.6% | — |
| Aug 7, 2023 | AMC | 1.55 | 1.88 | +21.3% | 171.44 | -10.5% | -16.6% | -17.0% | -17.2% | -16.9% | -16.7% | — |
| May 8, 2023 | AMC | 1.38 | 1.74 | +26.1% | 184.04 | +4.7% | +13.6% | +13.0% | +9.8% | +9.1% | +8.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $124.82 | $123.95 | -0.7% | -1.6% | -3.1% | -7.5% | -4.5% | -4.8% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $126.04 | $128.33 | +1.8% | +3.1% | +3.6% | +1.7% | +1.0% | -1.2% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $149.74 | $150.21 | +0.3% | +4.9% | +1.2% | +1.8% | +3.6% | +0.7% |
| Feb 20 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $149.74 | $150.21 | +0.3% | +4.9% | +1.2% | +1.8% | +3.6% | +0.7% |
| Nov 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $129.67 | $145.60 | +12.3% | +8.1% | +7.4% | +10.4% | +7.3% | +6.8% |
| Nov 7 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $129.67 | $145.60 | +12.3% | +8.1% | +7.4% | +10.4% | +7.3% | +6.8% |
| Oct 21 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $117.34 | $117.41 | +0.1% | +3.1% | +4.3% | +3.7% | +5.2% | +4.7% |
| Sep 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $130.57 | $131.65 | +0.8% | +2.3% | +3.4% | -0.1% | +1.2% | -0.2% |
| Aug 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $129.91 | $124.71 | -4.0% | -13.1% | -16.8% | -15.1% | -12.1% | -13.9% |
| May 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $142.87 | $135.35 | -5.3% | -3.2% | +1.0% | +0.5% | -4.9% | -1.6% |
| Apr 21 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $138.67 | $137.06 | -1.2% | -1.4% | -5.8% | -4.6% | -1.1% | -2.2% |
| Apr 8 | Needham | Maintains | Hold → Hold | — | $142.25 | $147.54 | +3.7% | -5.8% | +6.2% | -2.7% | +0.3% | -1.2% |
| Dec 11 | Jefferies | Upgrade | Hold → Buy | — | $160.11 | $167.49 | +4.6% | +3.8% | +3.4% | +1.0% | -0.7% | -1.8% |
| Nov 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $178.01 | $193.30 | +8.6% | -1.8% | -3.4% | -5.7% | -4.5% | -4.7% |
| Oct 15 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $180.30 | $180.73 | +0.2% | -0.4% | +2.0% | +0.1% | +0.4% | -0.8% |
| Sep 12 | Raymond James | Maintains | Outperform → Outperform | — | $170.42 | $172.15 | +1.0% | +2.2% | +5.0% | +5.3% | +3.4% | +3.4% |
| Aug 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $121.79 | $143.48 | +17.8% | +24.3% | +25.4% | +21.6% | +23.2% | +21.5% |
| Aug 8 | Raymond James | Maintains | Outperform → Outperform | — | $121.79 | $143.48 | +17.8% | +24.3% | +25.4% | +21.6% | +23.2% | +21.5% |
| Jun 17 | Raymond James | Upgrade | Market Perform → Outperform | — | $113.61 | $116.80 | +2.8% | +4.3% | +5.3% | +6.1% | +2.2% | +2.5% |
| Feb 28 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $106.81 | $112.15 | +5.0% | +5.3% | +2.3% | -1.3% | +0.1% | -4.0% |
| May 9 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $184.04 | $192.74 | +4.7% | +13.6% | +13.0% | +9.8% | +9.1% | +8.2% |
| Nov 8 | Raymond James | Downgrade | Outperform → Market Perform | — | $142.07 | $128.90 | -9.3% | +2.4% | +2.1% | +10.3% | +16.5% | +11.7% |
| Aug 9 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $188.10 | $170.00 | -9.6% | -11.6% | -8.9% | -9.9% | -9.0% | -6.6% |
| Aug 9 | Raymond James | Maintains | Outperform → Outperform | — | $188.10 | $170.00 | -9.6% | -11.6% | -8.9% | -9.9% | -9.0% | -6.6% |
| Aug 8 | Raymond James | Maintains | Outperform → Outperform | — | $179.63 | $179.12 | -0.3% | +4.7% | -7.4% | -4.6% | -5.7% | -4.7% |
| Aug 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $179.27 | $179.30 | +0.0% | -0.8% | -2.0% | +0.2% | +4.9% | -7.2% |
| May 10 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $201.17 | $187.48 | -6.8% | -8.2% | -13.8% | -13.2% | -12.9% | -10.2% |
| May 10 | Raymond James | Maintains | Outperform → Outperform | — | $201.17 | $187.48 | -6.8% | -8.2% | -13.8% | -13.2% | -12.9% | -10.2% |
| Feb 28 | Raymond James | Maintains | Outperform → Outperform | — | $228.95 | $227.04 | -0.8% | +3.4% | +3.0% | +3.0% | +4.9% | +6.1% |
| Oct 22 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $230.50 | $227.79 | -1.2% | -2.0% | -2.4% | -2.7% | -1.3% | -0.1% |
| Sep 9 | Raymond James | Maintains | Outperform → Outperform | — | $260.00 | $259.93 | -0.0% | -3.0% | -6.1% | -7.7% | -8.0% | -6.2% |
| Sep 9 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $260.00 | $259.93 | -0.0% | -3.0% | -6.1% | -7.7% | -8.0% | -6.2% |
| Aug 6 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $192.47 | $191.41 | -0.6% | +0.4% | +0.5% | -0.8% | -2.0% | -2.9% |
| Aug 5 | Raymond James | Maintains | Outperform → Outperform | — | $190.73 | $183.39 | -3.8% | +0.9% | +1.3% | +1.5% | +0.1% | -1.1% |
| Feb 26 | Raymond James | Maintains | Outperform → Outperform | — | $218.19 | $218.19 | +0.0% | -4.9% | -4.9% | -6.2% | -7.0% | -9.2% |
| Feb 11 | Raymond James | Maintains | Outperform → Outperform | — | $212.78 | $214.07 | +0.6% | +2.4% | +3.6% | +2.9% | +3.0% | +2.1% |
| Jan 8 | KeyBanc | Maintains | Overweight → Overweight | — | $219.99 | $219.96 | -0.0% | +0.7% | +1.2% | -1.1% | +0.9% | +0.6% |
| Nov 6 | KeyBanc | Maintains | Overweight → Overweight | — | $188.29 | $195.00 | +3.6% | -0.0% | +1.6% | +4.2% | +3.6% | +3.6% |
| Nov 6 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $188.29 | $195.00 | +3.6% | -0.0% | +1.6% | +4.2% | +3.6% | +3.6% |
| Sep 2 | KeyBanc | Maintains | Overweight → Overweight | — | $197.98 | $202.65 | +2.4% | +0.7% | -2.6% | -5.4% | -6.0% | -1.4% |
| Sep 2 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $197.98 | $202.65 | +2.4% | +0.7% | -2.6% | -5.4% | -6.0% | -1.4% |
| Aug 11 | Raymond James | Maintains | Outperform → Outperform | — | $178.88 | $197.21 | +10.2% | +8.1% | +5.7% | +5.6% | +4.3% | +3.1% |
| May 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $187.36 | $187.00 | -0.2% | -2.9% | -1.0% | -0.7% | -0.4% | +0.8% |
| May 13 | KeyBanc | Maintains | Overweight → Overweight | — | $187.36 | $187.00 | -0.2% | -2.9% | -1.0% | -0.7% | -0.4% | +0.8% |
| May 8 | Raymond James | Maintains | Outperform → Outperform | — | $217.36 | $211.55 | -2.7% | -8.9% | -7.7% | -13.8% | -16.3% | -14.7% |
| Mar 18 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $176.87 | $175.78 | -0.6% | +3.8% | +1.1% | -2.2% | -8.1% | +3.0% |
| Mar 18 | KeyBanc | Upgrade | Sector Weight → Overweight | — | $176.87 | $175.78 | -0.6% | +3.8% | +1.1% | -2.2% | -8.1% | +3.0% |
| Feb 28 | Raymond James | Maintains | Outperform → Outperform | — | $200.35 | $194.10 | -3.1% | -2.3% | +0.2% | -2.9% | -1.0% | -4.3% |
| Aug 8 | Raymond James | Downgrade | Strong Buy → Outperform | — | $245.67 | $169.00 | -31.2% | -33.3% | -32.1% | -31.1% | -31.6% | -33.0% |
| Mar 1 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $245.76 | $247.65 | +0.8% | +2.7% | -3.9% | -4.7% | -6.0% | -5.5% |
No insider trades available.
8-K · 5.02
!!! Very High
ICU Medical Inc -- 8-K 5.02: Executive Change
ICU Medical's Compensation Committee amended its Executive Severance Plan, potentially affecting executive retention and cost structures, though specific changes and financial impact details require full filing review.
Feb 20
8-K
ICU Medical Inc -- 8-K Filing
ICU Medical improved its gross margin to 38% in Q4 2025 from 36% year-over-year, indicating better operational efficiency and pricing power that should enhance profitability.
Feb 19
Data updated apr 25, 2026 2:55pm
· Source: massive.com